InnovITech has launched a new research and development initiative focused on infertility diagnosis and personalized therapy selection, based on AI-driven analysis of microbiome and metabolite data
InnovITech Ltd. is launching the development of an artificial intelligence–based IT platform that supports more accurate diagnosis of male infertility and personalized therapeutic decision-making through the integrated analysis of microbiome, gene activity, metabolite, and clinical data.
The development aims to implement an IT platform based on bioinformatics and machine learning. This platform analyzes the microbiome composition and bacterial gene activity in seminal plasma and stool, evaluates metabolite profiles in blood and stool, and correlates these findings with clinical data. The AI-driven exploration of correlations between microbiome, metabolite, and clinical data will be supported by extensive microbiological analyses and clinical data collection. This enables machine learning methods to identify complex, diagnostically and therapeutically relevant patterns and potential biomarkers
Building on these results, the system will effectively support diagnostic decision-making and contribute to the foundation of personalized therapeutic options.
The development will yield a digital platform providing practical solutions for clinics, research institutes, and laboratories, with the long-term potential to address other microbiome-related diseases.
The biotechnological and clinical expertise is provided by Labmagister, which, as a fertility diagnostic center with outstanding insight into the field, involves the necessary clinical stakeholders.
The project is being implemented within the framework of the Széchenyi Plan Plus program, with support from the Digital Renewal Operational Programme Plus (DIMOP Plusz). The development is co-financed by the European Union.
Project identification number: DIMOP_PLUSZ-1.1.2/B-24-2025-00067
Amount of non-refundable European Union support: HUF 243.222 million